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Abstract: Highly active antiretroviral therapy (HAART) has limited the replication and 
spread of the human immunodeficiency virus (HIV). However, despite treatment, HIV 
infection persists in latently infected reservoirs, and once therapy is interrupted, viral 
replication rebounds quickly. Extensive efforts are being directed at eliminating these cell 
reservoirs. This feat can be achieved by reactivating latent HIV while administering drugs 
that prevent new rounds of infection and allow the immune system to clear the virus. 
However, current approaches to HIV eradication have not been effective. Moreover, as 
HIV latency is multifactorial, the significance of each of its molecular mechanisms is still 
under debate. Among these, transcriptional repression as a result of reduced levels and 
activity of the positive transcription elongation factor b (P-TEFb: CDK9/cyclin T) plays a 
significant role. Therefore, increasing levels of P-TEFb expression and activity is an 
excellent strategy to stimulate viral gene expression. This review summarizes the multiple 
steps that cause HIV to enter into latency. It positions the interplay between 
transcriptionally active and inactive host transcriptional activators and their viral partner 
Tat as valid targets for the development of new strategies to reactivate latent viral gene 
expression and eradicate HIV. 
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1. Introduction 
Since its discovery 30 years ago, the human immunodeficiency virus (HIV) has turned from a 
highly epidemic threat to a persistent pathogen that co-exists with its host. This progress is mainly due 
to the administration of effective highly active antiretroviral therapy (HAART) that targets key viral 
enzymes, which are essential for the replication of HIV [1]. With the introduction of HAART, the 
spread of the virus has been substantially diminished and viral RNA levels can be reduced to clinically 
undetected levels in HIV-infected individuals [1]. Looking back at this troublesome period, one can 
acknowledge the medical achievements in restricting the virus and improving the quality of life and the 
survival of HIV-infected people worldwide.  
However, in two aspects of the battle against HIV, the medical community has failed to control the 
infection. First, an effective vaccine that can inhibit viral replication has not yet been developed. 
Second, viral infected cell reservoirs that appear early in the infection accumulate in sites that resist 
eradication of the virus by the currently available antiretroviral therapies. As these pools are highly 
stable, life-long HAART is required, which, in turn, causes severe side effects and promotes the 
evolution of viral-resistant strains [2]. 
 
2. Events of Productive HIV Infection  
 
HIV latency is a multifactorial process. However, the importance of each molecular pathway is still 
under debate. Latency can be defined as a reversible low-productive state of infection, where infected 
cells retain the capacity to produce new viral particles [3]. For productive infection to occur, target 
cells need to be activated. In T cells, this feat can be achieved via a wide range of stimuli, including T-
cell receptor (TCR) and co-receptor ligation by anti-CD3 and anti-CD28 antibodies, cytokines (IL-1, 
IL-7, and TNF) and PKC modulators (PMA or prostratin) [4-10]. These non-specific stimuli increase 
levels of required transcription factors and de-compact chromatin, rendering it accessible for initiation 
and elongation of HIV transcription. For the former, transcription factors, such as TBP, TAFs, Sp1, 
AP-1, cMyb, GR, C/EBP, Ets-1, LEF-1 and IRF bind to the HIV promoter [2,12,13,14]. For the latter, 
NFB and NFAT [11] are recruited to the HIV enhancer. A functional equilibrium between histone 
acetyl-transferases (HATs; p300/CBP, PCAF and CN5) and histone deacetylases (HDACs) also affect 
transcription initiation. Basal transcription factors then position RNA polymerase II (RNAPII) on the 
HIV transcription start site (TSS). This step is followed by the phosphorylation of serine residues at 
position 5 (S5) in the heptapeptide (YSPTSPS)52 repeats of the C-terminal domain (CTD) of RNAPII 
by TFIIH/Cdk7. However, on most eukaryotic genes, RNAPII quickly pauses close to the TSS. 
Pausing of RNAPII occurs also on immediate response genes that are required for cells subjected to 
acute stress signals. These genes regulate a synchronous expression of downstream effectors that alter 
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transcriptional networks and mediate the adaptation of cells to stress [15]. 
Early nuclear run-on and RNase protection studies in resting cells demonstrated that transcription 
does not elongate far on the HIV LTR, and that only short, abortive viral transcripts are generated. In 
part, this strong block is due to the 5’ stem-loop trans-activating response (TAR) RNA structure, which 
binds tightly to negative transcription elongation (NELF) and to DRB sensitivity inducing (DSIF) 
factors. After stalling, RNAPII is released and begins to elongate only after the recruitment of positive 
transcription elongation factor b (P-TEFb) to the viral promoter via NFkB, bromo-domain-containing 
protein 4 (Brd4) in the Mediator, or the super elongation complex (SEC) [16]. In resting cells, this 
interplay between positive and negative factors silences HIV transcription, as P-TEFb associates 
mainly with its inactive partners. However, after the synthesis of Tat, RNAPII begins to elongate 
efficiently and HIV replication resumes [17]. Tat binds to the bulge region of TAR via its arginine-rich 
motif (ARM), and to cyclin T1 (CycT1) of P-TEFb through its cysteine-rich activation domain [18]. 
Tat also interacts with HATs, p300/CBP and PCAF. These interactions lead to the recruitment of the 
chromatin remodeling complex SWI/SNF/BAF, which de-compacts chromatin and facilitates 
transcription elongation by displacing restrictive nucleosomes [19-24]. Stress signals release more P-
TEFb from its inhibitory complex to increase its kinase activity and stimulate the proliferation of cells. 
The main targets of P-TEFb phosphorylation are NELF and DSIF. CDK9 phosphorylates SPT5 of 
DSIF and the E/RD RNA binding subunit of NELF, removing RD from TAR and converting DSIF 
into an elongation factor. These steps release RNAPII from pausing and reverse negative effects of 
NELF and DSIF on transcription elongation [25-27]. CDK9 phosphorylates serine residues at position 
2 (S2) in the CTD of RNAPII, which assures proper co-transcriptional processing of nascent viral 
transcripts [18,28-33].   
P-TEFb was isolated initially from fruit flies as a general transcription factor whose kinase activity 
was inhibited by the ATP analog 5,6-Dichlorobenzimidazole 1- -D-ribofuranoside (DRB) [34,35]. As 
Tat transactivation is also inhibited by DRB, P-TEFb was suggested to mediate effects of Tat [36]. 
Indeed, biochemical analyses identified the Tat associated kinase (TAK) as the cdc2-like cyclin-
dependent kinase, PITALRE [37,38,39,40]. Later, PITALRE was identified as CDK9 [30,35,41]. 
Finally, CycT1 was isolated as the host co-factor that binds to Tat [18]. Genetic data supported these 
important biochemical breakthroughs. Chromosome 12, which codes for CycT1, was shown to be 
essential for optimal interactions between Tat and TAR [42,43]. Additionally, a cysteine at positions 
261 in the human CycT1, which is a tyrosine in the murine CycT1, was found to be critical for the 
binding between Tat and CycT1, clarifying the block to Tat transactivation in rodent cells [44].  
P-TEFb consists of CDK9 and one of three C-type cyclins, CycT1, CycT2a and CycT2b [45]. 
However, only CycT1 is the cellular co-factor for Tat. In contrast to CycT1:CDK9, levels of these 
additional P-TEFb complexes do not vary following activation of CD4+ T cells, or macrophage 
differentiation [46]. Moreover, they are thought to regulate transcription of different subsets of genes 
[47]. Thus, CycT2 plays a critical role in mouse embryonic stem cells, and its knockout leads to 
embryonic lethality in mice [48]. It is also expressed at high levels in adult human skeletal muscle cells 
and plays an important role in their differentiation [49]. Cumulatively, these results suggest that the 
degree of redundancy in gene regulation by CycT1 or CycT2 is cell type- and tissue-specific. A third 
cyclin, CycK, was also thought to partner with CDK9, but was demonstrated later to bind to CDK12 
and CDK13 to regulate DNA damage response genes [50,51,52,53]. Indeed, S2 phosphorylation 
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depends greatly on CDK12/13 and possibly CDK11. CycK, CDK12 and CDK13 are also highly 
expressed in pluripotent embryonic stem cells, but not in their differentiated derivatives or tissue-
specific stem cells [54]. In contrast, stable interactions between Tat and P-TEFb lessen the role of 
these other CTD kinases in HIV transcription.  
Along with using HIV as a model for studying transcription elongation [55], reports on the heat 
shock 70 (Hsp70) promoter also confirmed the importance of RNAPII pausing as a regulatory step of 
gene expression [56,57]. Later, other host co-activators such as CIITA and c-Myc were found to 
associate with P-TEFb for the expression of their target genes [58,59]. The regulation of RNAPII 
pausing has also been linked to later steps of transcription, such as splicing and 3’ end formation [60]. 
Although mRNA capping occurs during RNAPII pausing and is stimulated by DSIF [61,62,63], P-
TEFb also promotes co-transcriptional mRNA processing and mRNA export [64-67]. CycT1 also 
interacts with the cellular splicing factor SKIP, which facilitates Tat-mediated transactivation of HIV 
[68]. In addition, Tat can affect splice site recognition via the ASF/SF-2 alternate splicing complex 
[69,70]. Cellular mRNA capping proteins Mce1 and Hcm1, which stimulate co-translational capping 
and stabilization of nascent HIV transcripts, also associate with Tat and increase HIV gene expression 
[71,72]. Finally, the capping protein binding complex (CBC) can interact with P-TEFb and RNAPII 
and is required globally for optimal levels of S2 phosphorylation in the CTD of RNAPII. These 
findings demonstrate a vital role of CBC in connecting pre-mRNA capping to transcription elongation 
and alternate splicing via P-TEFb [64,65,67].  
The crystal structure of the Tat:P-TEFb complex reveals that Tat forms extensive contacts with 
CycT1 and with the T-loop of CDK9 [73]. This structure explains how sequence variation in Tat is 
tolerated at certain sites. Importantly, Tat also increases the kinase activity of P-TEFb. These findings 
suggest that the Tat·P-TEFb complex formation could be disrupted, which might inhibit HIV 
replication [73]. 
3. Mechanisms that Enforce Entrance of HIV into Latency  
The infection of HIV results in the integration of many replication-defective proviruses into the host 
genome. In other activated cells, a fully competent provirus will integrate and replicate efficiently. 
Often, these cells will produce infectious viral particles until they are eliminated by cytolytic T cells or 
die from direct cytopathic effects of the virus. Entrance into a transcriptionally silent state will occur 
when sub-optimally activated infected cells escape the immune surveillance and become quiescent 
[2,3,10,74,75]. Establishment and persistence of latency will then correlate with low levels of host cell 
factors such as NFB and P-TEFb, which impose limitations on rates of transcription. A hallmark of 
this repression is the absence of Tat, which acts as a master switch for productive HIV transcription. 
Below are depicted additional pathways that drive the virus into latency and maintain transcriptional 
repression. 
3.1. Epigenetic Constraints– Impact on Transcription Initiation 
It is now well established that the profile of chromatin around the integrated provirus influences 
viral transcription. As heterochromatin is more compact and structured than euchromatin, it is 
repressive for transcription. The compaction of chromatin and its accessibility for transcription factors 
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depend on post-translational modifications of histones and epigenetic marks. These dictate the rates of 
transcription initiation and ultimately the levels of Tat. The architecture of chromatin is also influenced 
by the activation state of the infected cell. In a quiescent state, protein modifying enzymes that are 
recruited favor chromatin condensation. Around the integrated latent provirus, the Nuc-1 restrictive 
nucleosome becomes the main target for histone modifications. Open chromatin is then characterized 
by several histone H3 modifications: H3K9Ac, H3K4me, H3K14Ac H3K27me1, H3K36me and 
H3K79me. In a condensed chromatin state around the HIV LTR, H3K9m2, H3K9m3, H3K27me2 
H3K27me3, H3K79me and H4K20me are commonly found and lessen the accessibility of 
transcription factors to the viral promoter. These changes affect pre-initiation complex (PIC) assembly 
as well as RNAPII pausing, thus providing multiple blocks to viral gene expression [76,77-79]. They 
also reflect the site of proviral integration into the host genome, which contributes to this 
transcriptional silencing. Several histone methyltransferases modify histones. SUV39H1 and G9a are 
involved in heterochromatin formation at the HIV promoter and as a consequence, increase HIV gene 
silencing [80,81]. G9a inhibits basal and induced HIV gene expression by TNFα or Tat [82]. In 
addition to the equilibrium between histone acetyltransferases (HATs) and histone deacetylases 
(HDACs), several other components are also involved in their recruitment to the viral promoter. Ying 
Yan 1 (YY1) and the late SV-40 (LSF) transcription factors specifically and synergistically repress 
HIV transcription initiation and viral production via recruitment of HDACs. That HIV can be 
reactivated by HDAC inhibitors, e.g. Trichostatin A, SAHA (suberoylanilide hydroxamic acid) or 
Trapoxin [77], also supports a role for HDACs in the establishment of HIV latency [83-85]. Other host 
factors that recruit HDAC-I to the HIV LTR, include p50 homodimers and the transcriptional repressor 
c-promoter binding factor (CBF-1), which is a key regulator of the notch signaling pathway, Both bind 
to the NFB motifs in the HIV enhancer [86,87]. In agreement with the above data, activation of HIV 
gene transcription via NFB leads to the displacement of CBF-1 from the LTR as well as the 
recruitment of HATs and chromatin-remodeling factors. Low levels of basal transcription factors, 
NFB and NFAT, further restrict HIV transcription initiation, and ensure that latent proviruses remain 
transcriptionally silenced for long periods of time [88-91].  
In addition to histone methylation, DNA methylation at CpG islands near the HIV promoter has 
been also correlated with repressive HIV transcription in transformed cell lines but not in primary cells 
[78.88]. Nevertheless, clearance of HIV from infected patients can be increased by the addition of 
DNA methylation inhibitors, such as aza-CdR, or NF-B activators [88,92]. Moreover, the SWI/SNF 
chromatin remodeling complex BAF, but not PBAF, facilitates the establishment of latency via 
repressive nucleosome positioning on the HIV LTR [93]. Thus, epigenetic histone modifications and 
chromatin remodeling machineries, but not DNA methylation, play important roles in HIV latency 
(Figure 1). 
 
Figure 1. Epigenetic control modulates HIV latency. A) In activated T cells, levels of 
transcription factors (NFB and NFAT) are elevated, which increases rates of HIV 
transcription. NFB (p50/RelA) is tethered to the HIV LTR and recruits P-TEFb, HATs 
and the SWI/SNF remodeling machinery. This leads to an overall de-compaction of 
chromatin and higher accessibility for other transcription factors. B) Upon entering the 
resting state, low levels of transcription factors, NFB, NFAT and co-activators, P-TEFb, 
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decrease HIV transcription. They also reduce levels of Tat. Epigenetic modifications in the 
form of de-acetylation of histones as well as methylation of histones and DNA increase the 
compaction of chromatin and contribute to repression of HIV gene expression. The 
polycomb repressive complex-2 (PRC2) mediates methylation of histones and DNA, thus 
inducing gene silencing. HDACs are recruited via p50 homodimers, CBF-1, YY1, AP4, 
and/or COUP-TF-interacting protein 2 (CTIP2). 
 
3.2. Transcriptional Interference—TI 
As mentioned above, for the establishment of latency, HIV integration sites are critical. HIV prefers 
to integrate into transcriptionally active genes [94,95], where chromatin is relatively open. Less 
frequently, HIV integrates near centromeric alphoid repeats, or into gene deserts [96-100]. By 
integrating into active genes, there is a trade-off. While “relaxed” epigenetic patterns around active 
genes supports integration events and activators assembly on the promoter [78,79], transcriptional 
interference (TI) between the host and viral promoters displaces transcription factors from the HIV 
LTR and promotes transcriptional repression. Indeed, RNAPII from the upstream host promoter 
displaces key transcription factors, like Sp1 and TAFs [97,99,101,102]. In this scenario, ongoing 
transcription from a host promoter prevents the PIC assembly. Limiting host cell co-activators in the 
resting state also promote this form of latency.  
In both orientations, the host RNAPII displaces transcription factors and represses HIV transcription 
at the HIV LTR. Although RNAPII terminates in the 5’ HIV LTR in the sense orientation, in the 
antisense orientation, it reads through the entire HIV provirus and generates antisense transcripts that 
are degraded. TI is also a prerequisite for normal viral replication, as HIV needs low affinity 
transcription factor-binding sites so that it can terminate transcription and polyadenylate viral 
Viruses 2013, 5                            
 
 
908 
transcripts at its 3’ HIV LTR. In TI, the host promoter has an advantage: it is not occluded and its 
affinity for transcription factors can be higher.  
In intermediate cases where the host gene is not transcribed efficiently, HIV can overcome TI and 
activate its replication. Given the preferential integrations of viral genomes into active genes 
[97,99,103], TI is a widespread phenomenon and operates in concert with other mechanisms that 
enforce latency (Figure 2). 
Figure 2. TI promotes HIV latency. HIV provirus integrates into actively transcribed 
genes where chromatin is de-compacted and DNA is accessible to the transcriptional 
machinery. However, this location also leads to the competition between the integrated 
viral and host promoters, resulting in transcriptional interference (TI). The provirus 
integrates in the same or opposite polarity to its host gene. Either way, transcription that 
initiates from the host gene displaces transcription factors that assemble on the HIV LTR, 
leading to the silencing of proviral gene expression. In the sense orientation, RNAPII 
terminates in the 5’ HIV LTR and displaces transcription factors (Sp1/TAFs) (upper 
panel). In the antisense orientation, transcription factors are displaced from both HIV 
LTRs; extended antisense HIV transcripts are generated and degraded in infected cells 
(lower panel). 
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3.3 The Dynamic between Transcriptionally Active and Inactive P-TEFb Controls HIV Transcription  
Paralleling the regulation of transcription initiation that limits levels of Tat and blocks productive 
transcription, levels of free active P-TEFb that can bind activators are also tightly regulated in cells. In 
them, levels of free P-TEFb are restricted, and most of it is found in the large 7SK small nuclear 
ribonucleoprotein (snRNP). 7SK snRNP consists of the small 7SK nuclear RNA [snRNA], the 
hexamethylene bisacetamide [HMBA]-inducible protein 1 [HEXIM1], the lupus antigen (La)-related 
protein 7 [LARP7] and the methylphosphate-capping enzyme [MePCE] [104]. 7SK snRNA acts as a 
scaffold for the assembly of HEXIM1 and P-TEFb. In this complex, P-TEFb is inactive due to 
conformational changes of HEXIM1 bound to 7SK snRNA, which blocks the CDK9-ATP binding 
pocket [105]. The disassembly of the 7SK snRNAP and release of P-TEFb are facilitated by activation 
and stress signals like apoptosis, UV light, actinomycin D and P-TEFb kinase inhibitors. Acetylation 
of CycT1 also liberates P-TEFb from its inactive complex [106]. In addition, Tat and the host Brd4 can 
extract P-TEFb from the 7SK snRNP. Brd4 also associates with acetylated histones via its 
bromodomains [107].  
The P-TEFb interacting domain (PID), which is located at the C-terminus of Brd4, is essential for 
its binding to P-TEFb [108-110]. However, almost all Brd4 is associated with interphase chromatin in 
untreated cells. Upon stress, Brd4 is released from acetylated chromatin via histone deacetylation, and 
this step is essential for the recruitment of active P-TEFb to promoters and for transcription elongation 
[111,112]. The second bromodomain motif (BDII) of Brd4 also binds to the acetylated CycT1, thus, 
interactions between CycT1 and Brd4-tethered chromatin could be mutually exclusive [113]. How P-
TEFb-Brd4 complexes transit to and from chromatin in response to external stimuli is still not well 
understood. The accepted model argues that, following stimulation, the release of P-TEFb from the 
inactive 7SK snRNP and from chromatin is triggered, thereby allowing Brd4 in the Mediator to recruit 
P-TEFb to the promoter [114] (Figure 3). 
Brd4 and Tat also accelerate the dynamics of mRNA synthesis by supporting chromatin  
de-compaction and inducing gene activation [115]. Other signals that will be discussed below also lead 
to T-cell activation and disrupt the 7SK snRNP [46]. These activation signals ultimately alter 
chromatin structure around the integrated provirus and de-compact it, thus stimulating transcription via 
basal and Tat-dependent mechanisms [116-119] (Figure 3). 
 
3.4 Regulation of P-TEFb Expression and Activity 
 
Levels of P-TEFb subunits are low in resting CD4+ T cells and monocytes [120,121], but are 
dramatically elevated upon activation [46,122,123,124]. Increased expression levels also occur upon 
differentiation of monocytes to macrophages. In macrophages, proteasome-mediated proteolysis of 
CycT1 limits the expression of CycT1 via its C-terminal PEST sequence [125,126]. In addition, in 
resting monocytes and CD4+ T cells, miR198 and miR27b, 29b, 150 and 223 repress CycT1 
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expression, respectively [121,127,128]. Nuclear factor 90 (NF-90) also binds to the 3’-UTR of CycT1 
and regulates its expression [129].  
Other post-translational modifications also affect P-TEFb activity. For example, the C-terminal 
region of CDK9 is auto-phosphorylated and mediates binding to other transcription factors like Tat 
SF1 and RNAPII and perhaps additional components of the elongation apparatus [130,131]. The un-
phosphorylated CDK9 and the C-terminus of CycT1, which folds back to interact with its N-terminus 
also inhibit the TRM in CycT1. Relief of this auto-inhibition in CycT1 involves a conformational 
change in CycT1, which unmasks critical TRM sequences and requires the auto-phosphorylation of 
CDK9 (see below) [18,131-133]. Lysine residues located in the coil–coil region of CycT1 are 
acetylated and mediate association of P-TEFb with Brd4, which can extract P-TEFb from the 7SK 
snRNP [106,134].  
 
Figure 3: Interplay between positive and negative complexes regulates P-TEFb 
transcriptional activity. In resting cells, the binding of CycT1 to HEXIM1 in the 7SK 
snRNP inactivates the kinase activity of P-TEFb. In conjunction with low expression levels 
of P-TEFb and basal transcription factors, transcription is repressed. Activation of CD4+ 
T-cells or monocytes increases the expression and kinase activity of P-TEFb. Indicated 
stress signals release P-TEFb from its inactive complex and subsequently lead to its 
recruitment to the HIV LTR as an active complex, which stimulates transcription 
elongation. Low levels of specific miRNA that target CycT1 also contribute to P-TEFb 
activation and cell proliferation. By releasing Brd4 from chromatin, I-BET or JQ1 liberate 
P-TEFb from the 7SK snRNP and stimulate HIV transcription. 
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CDK9 expression levels and activity are also tightly regulated and depend on the activation and 
differentiation state of the cell, based on the cell’s metabolic demands [135,136]. In cells, there exists 
two isoforms of CDK9, which measure 42 kDa and 55 kDa. They differ in their N-terminal region and 
are transcribed from different promoters. These two isoforms share different sub–cellular localizations 
and expression patterns. Immunofluorescence studies revealed that whereas the 42-kDa variant of 
CDK9 is present in nuclear speckles [137,138], the 55-kDa isoform is localized to the nucleolus [139]. 
Moreover, total CDK9 expression levels are elevated upon cell activation, mainly due to an increase of 
the 42 KDa isoform [139]. Similarly, the kinase activity of CDK9 is also limited in resting primary 
cells.  
Basal T-loop (amino acids 168–197) phosphorylation of CDK9 is extremely low in resting CD4+ T-
cells [122,123], which further limits P-TEFb activity. Following T-cells activation and CycT1 
induction, T-loop phosphorylation increases rapidly. CDK9 is also phosphorylated at other residues 
(T29, S90, T186, S175, S347, T362, T363) [132,140-144]. These phosphorylation events induce a 
conformational change of the T loop, allowing entry of the substrate and ATP into the CDK9 catalytic 
pocket [145]. Thus, the T186 phosphorylation in the conserved T-loop of CDK9 is the critical event 
for optimal CDK9 activity and association with the 7SK snRNP [140,144]. At present, this kinase 
remains poorly characterized. Some reports suggest that CDK9 itself can phosphorylate Thr186, which 
is influenced by Tat or TFIIH [130,131,146]. This situation would be analogous to the auto-
phosphorylation of the C terminus of CDK9 on S347, T350, S353, T354 and S357 that also facilitates 
the assembly of P-TEFb onto TAR [131]. However, the kinase activity of a purified P-TEFb 
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inefficiently auto-phosphorylates T186 in vitro, pointing to the involvement of another kinase 
[110,132,143]. To this end, CDK2 and CDK7 were also identified as potential CDK9 kinases 
[147,148]. T186-phosphorylated CDK9 is mainly found within the inactive P-TEFb complex [110]. 
Accordingly, a de-phosphorylation step of CDK9 is important to recycle P-TEFb and regulates its 
dissociation from the 7SK snRNP [140]. Several phosphatases affect this phosphorylation state of 
CDK9. The calcium-sensitive and calmodulin-activated serine/threonine phosphatase PP2B and the 
alpha subunit of protein phosphatase 1 (PP1α) as well as manganese- or magnesium-dependent protein 
phosphatase 1A and 1B (PPM1A and PPM1B) affect the phosphorylation of T186. PP1α and PP2B, 
cooperatively release P-TEFb from the 7SK snRNP [110,149,150]. In this scenario, PP2B induces 
conformational changes in P-TEFb that allow for subsequent dephosphorylation of T186 by PP1α. 
PPM1A also associates with CDK9 and can de-phosphorylate it regardless of its association with 7SK 
snRNA. PPM1B does so only when 7SK snRNP is depleted [151]. CDK9 is also poly-ubiquitylated, 
which targets it for proteolysis via the SCF (Skp1-Cul1-F-box protein) complex, where CycT1 binds to 
SKP2 [141,152]. Similarly to CycT1, CDK9 is acetylated, presumably on K40 and K44 residues. Since 
an acetylation-defective mutant CDK9 (K44R) and CDK9 isolated from cells over-expressing HDAC1 
or HDAC3 are kinase deficient, the acetylation of CDK9 might be important for its kinase activity. 
p300 or members of the GCN5-related N-acetyltransferase (GNAT) family (GCN5 and PCAF) 
mediate this CDK9 acetylation. These effects are direct and impact the kinase activity of CDK9 
[142,153]. 
 
3.5 SEC Associates with HIV Tat and Activates Viral Transcription 
P-TEFb is not the only complex that is recruited by Tat to the viral promoter. In a search of other 
Tat co-factors, biochemical affinity-purification strategies identified a SEC that consisted of ELL2, 
AFF4, ENL, AF9 in addition to Tat and P-TEFb [154-156]. ELL1 and ELL2 are well-characterized 
transcription elongation factors that stimulate the activity of RNAPII by keeping the 3’-OH of nascent 
mRNA in alignment with the catalytic site and preventing RNAPII backtracking [157,158,159].  
Tat stabilizes ELL2 levels and promotes SEC formation. Despite being in a same complex with Tat, 
SEC also recruits P-TEFb to the vicinity of RNAPII and increases basal transcription in the absence of 
Tat. Indeed, SEC interacts efficiently with RNAPII via the Mediator and/or the human polymerase-
associated factor complex (PAFc) transcription elongation complexes [160] (Figure 4). 
Figure 4: Recruitment mechanisms of P-TEFb to promoter. The efficient transcription 
of signal-inducible genes relies on the release of P-TEFb from its inactive complex and 
also on its recruitment to promoters. Recruitment of P-TEFb to viral and host promoters 
leads to stimulation of transcription, thus releasing RNAPII from pausing. Several 
pathways exist for the recruitment of P-TEFb to the HIV LTR. Among them, Tat-
independent basal transcription includes recruitment via NFB, Brd4 and SEC in the 
Mediator. Elongation of transcription is enhanced by Tat, which binds P-TEFb and tethers 
it to TAR.  
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(i) Basal transcription from the HIV LTR is maintained by P-TEFb that is recruited 
to target genes via Brd4 and SEC in the Mediator, which is part of the RNAPII 
holoenzyme. Herein, Med26 or Cdk8 tether SEC to the Mediator. Within SEC, AFF4 binds 
to CycT1 and acts as a scaffold that connects P-TEFb to ELL2, which also stimulates 
transcription. In ENL/AF9 of SEC, the YEATS motif binds RNAPII-associated factor 1 
(PAF1) complex and is also recruited to RNAPII in chromatin. P-TEFb may be also 
recruited to the promoter via Brd4 in the Mediator. This interaction involves tri-acetylated 
CycT1 and is mediated by the P-TEFb interacting domain (PID) in the C-terminal region 
of Brd4 and the second bromodomain in Brd4 (BDII). Additionally, the BDII domain of 
Brd4 associates with acetylated chromatin. However, this interaction does not include 
active P-TEFb.  
(ii) P-TEFb is also recruited to the HIV promoter in a Tat-independent mechanism. 
NFB binds to DNA, tethers CycT1 to the LTR and increases rates of initiation and 
elongation of transcription.  SEC binds to P-TEFb and is in the same complex.  
 
 
4. Therapeutic Approaches 
A stable latent reservoir of HIV in resting memory CD4+ T cells is a major barrier for complete 
viral eradication [2,161,162,163]. Efforts to purge latent HIV have initially focused on reactivating 
latent proviruses with IL-2 alone or in combination with anti-CD3 antibodies. However, these 
strategies resulted in severe side effects and had low efficacy. Improved tools should induce HIV 
transcription without activating cells of the immune system [164,165,166]. In tissue culture, T-cell 
activation agents like IL-7 [167,168], PKC modulators (phorbol esters (phorbol-12-myristate  
13-acetate, PMA), prostratin or bryostatin-1 [169,170]), disulfiram [bis(diethylthiocarbamoyl) 
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disulfide], which inhibits aldehyde dehydrogenase [171][172], hexamethylene bisacetamide (HMBA), 
which induces terminal differentiation and apoptosis in transformed cells in culture [173–176], and 
HDAC inhibitors valproic acid and SAHA [177,178,179] have all been tested. These compounds 
stimulate HIV replication by inducing P-TEFb activity and promoting changes in chromatin. Other 
pathways like recruitment of active NFB, NFAT and other transcription factors to the viral promoter 
are also essential for viral reactivation. Clinical studies with valproic acid suggested that they decrease 
levels of latent viral reservoirs [177-181]. Suberoylanilide hydroxamic acid (SAHA; vorinostat), which 
has been approved for the treatment of cutaneous T cell lymphoma, releases P-TEFb from the 7SK 
snRNP and activates HIV transcription [182,183]. Vorinostat could become a component of the “shock 
and kill” approach, where a “shock” phase reactivates latent proviruses then a “kill” step limits viral 
replication and spread with HAART [183]. The assumption is that, following the reactivation of the 
virus, HIV-infected cells will die as a result of host immune responses and/or viral cytopathic effects 
[184]. However, recent experiments with SAHA in infected patients treated with HAART revealed 
inadequate levels of CD8+ T-cell-mediated cytotoxic killing of reactivated cells. It is possible that 
higher concentrations of SAHA, possibly with the combination of other compounds, could lead to 
higher levels of HIV protein expression, thus higher cytopathic effects of the virus. Alternatively, 
boosting anti-HIV CTLs via vaccination prior to reactivating latent proviruses may be required for  
HIV eradication [3]. 
Initiation events facilitate the accumulation of Tat, which binds to CycT1 and TAR to recruit P-
TEFb to the HIV LTR. In a Tat-dependent pathway, P-TEFb mainly supports transcription elongation 
by phosphorylating subunits of NELF and DSIF to release RNAPII from its pausing on the HIV 
promoter. P-TEFb also phosphorylates S2 in RNAPII CTD. Tat also associates with the SEC. 
The use of compounds that reactivate HIV must occur in the presence of HAART, which will 
prevent re-infection by replication-competent viruses. Inhibitors of the BET bromodomain - JQ1(S) 
and I-BET (bromodomain and extraterminal (BET) proteins) - which are in clinical studies for the 
treatment of several types of cancers including multiple myeloma, also activate HIV gene 
transcription. They bind to Brd4 (and other members of this family of structural proteins) and displace 
it from acetylated chromatin and the viral promoter. As a consequence, P-TEFb is released from the 
7SK snRNP. Since other members of the BRD family also play important roles, these studies point to 
new targets for BET bromodomain inhibition in HIV infection [185-186].  
Overall, an intelligent therapy will likely include a combinatorial approach that will change 
chromatin, increase the synthesis of P-TEFb as well as release it from the 7SK snRNP. Since P-TEFb 
levels are extremely low in primary infected resting hematopoietic cells, [120,121], PKC and TLR 
agonists must first increase their levels. Only then can HDAC or BET bromodomain inhibitors be 
applied and become effective. These compounds can be administrated, together or sequentially, to 
relax chromatin and release P-TEFb from its inactive complex. Indeed, little effect of HDACis alone 
has been reported in primary resting CD4+ T-cells [86,187,188], presumably because levels of P-TEFb 
are so low. PKC agonists will also induce NFB, thus stimulating transcription initiation and NFB-
mediated recruitment of P-TEFb. Lower doses of these agonists for longer cycling periods could lead 
to a functional cure, which will allow the immune system to keep the virus in check. These 
manipulations will ultimately cause cells to initiate DNA stress responses and avoid death via NFB 
and P-TEFb. The release of P-TEFb increases the synthesis of HEXIM1, which restores the P-TEFb 
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equilibrium that not only prevents cell activation and proliferation but hastens the demise of HIV-
infected cells. 
 
5. Conclusions 
 
To date, only HAART and stem cell transplantation from a CCR5-deleted donor cleared HIV from 
an infected adult [189]. Thus, the complex network that maintains HIV latency represents a major 
obstacle to the eradication of the virus. Currently tested drugs that successfully reactivate HIV are still 
not proven to be effective. At the same time, HAART cannot block ongoing viral replication especially 
in privileged anatomical sites. Cell-to-cell viral spread also contributes to drug insensitivity and 
hampers complete suppression of HIV replication.  
Nevertheless, new insights into pathways that drive HIV into latency, as well as the understanding 
of the molecular mechanisms by which HDAC or BET bromodomain inhibitors activate latent HIV are 
essential for the development of new therapeutic approaches to the eradication of HIV.  
We understand today that a combinatorial or synergistic approach will have to take place, as PKC 
agonists, P-TEFb disruptors and chromatin stress modulators are all partially effective. Issues of drug 
penetration into tissues also need to be addressed, as viral reservoirs tend to accumulate in poorly 
accessible sites. 
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